Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Exploratory Clinical Study to Evaluate the Safety and Efficacy of Elranatamab for Inhibitor Eradication in Patients With Moderate-to-Severe Hemophilia A With Inhibitors and Poor Prognosis for Inhibitor Eradication

NCT07788469 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07788469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07788469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Exploratory Clinical Study to Evaluate the Safety and Efficacy of Elranatamab for Inhibitor Eradication in Patients With Moderate-to-Severe Hemophilia A With Inhibitors and Poor Prognosis for Inhibitor Eradication
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitors